Epidemiology of drug hypersensitivity reactions using 6-year national health insurance claim data from Korea
- 132 Downloads
Background Drug hypersensitivity reactions (DHRs) constitute a large portion of adverse drug reactions (ADRs), but studies for DHR incidence based on national data are scarce. Objective This study aimed to estimate the incidence and patterns of DHRs in a Korean population and the associated utilization of medical resources using the national claims data. Setting The retrospective cohort study performed using the national insurance claim database of the Health Insurance Review and Assessment (HIRA) in Korea. Methods The International Classification of Disease 10th revision code was used to identify DHRs with 20 drug induced DHR codes. The claim data with a diagnosis of DHR in the 2009-2014 periods were analyzed. Main outcome and measure The annual incidence and the 6-year incidence rates were calculated. Incidence rate coefficients were analyzed by sex, age, and year. DHRs following with visits of emergency department (ED) or intensive care unit (ICU) were assessed for utilization of medical resources and risk of ER or ICU visits by sex and age Results A total of 535,049 patients with 1,083,507 claims were assessed in the HIRA database for 6 years. DHR incidence was high in the elderly. The risk of ED and ICU visit with DHR was also higher in the elderly than in the young [highest relative risk, RR of ED 2.59 (1.65–4.07), ICU 5.04 (2.50–10.18)]. DHRs related to blood were high in the young age. Conclusion Incidence of DHRs in the real-world clinical practice was higher in the elderly and female. Clinical consequence was more severe in the elderly.
KeywordsAdverse drug reactions (ADRs) Drug hypersensitivity Health insurance database Incidence Korea
This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation funded by the Ministry of Science, ICT & Future Planning, Republic of Korea (No. 2013M3A9B5075838).
Conflicts of interest
The authors have no conflicts of interest that are directly relevant to the content of this study.
- 6.Doña I, Barrionuevo E, Blanca-Lopez N, Torres M, Fernandez T, Mayorga C, et al. Trends in hypersensitivity drug reactions: more drugs, more response patterns, more heterogeneity. J Investig Allergol Clin Immunol. 2014;24:143–53.Google Scholar
- 9.Turner PJ, Gowland MH, Sharma V, Ierodiakonou D, Harper N, Garcez T, et al. Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992–2012. J Allergy Clin Immunol. 2015;135(956–63):e1.Google Scholar
- 22.Kano Y, Tohyama M, Aihara M, Matsukura S, Watanabe H, Sueki H, et al. Sequelae in 145 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: Survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR). J Dermatol. 2015;42:276–82.CrossRefGoogle Scholar
- 26.Hierro Santurino B, Mateos Conde J, Cabero Moran MT, Miron Canelo JA, Armentia Medina A. A predictive model for the diagnosis of allergic drug reactions according to the medical history. J Allergy Clin Immunol Pract. 2016;4(292–300):e3.Google Scholar
- 49.Tanno LK, Calderon M, Papadopoulos NG, Demoly P, EAACI/WAO Task force of a Global Classification of Hypersensitivity/Allergic diseases. Mapping hypersensitivity/allergic diseases in the International Classification of Diseases (ICD)-11: cross-linking terms and unmet needs. Clin Transl Allergy. 2015;5:20.CrossRefGoogle Scholar
- 50.Tanno LK, Calderon MA, Demoly P. Joint Allergy Academies. New allergic and hypersensitivity conditions section in the International Classification of Diseases-11. Allergy Asthma. Immunol Res. 2016;8:383–8.Google Scholar